SCHEDULE 13G/A: BlackRock Discloses 5.8% Stake in Ocular Therapeutix
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.8% beneficial ownership stake in Ocular Therapeutix, Inc. as of September 30, 2025.
Summary
- BlackRock, Inc. beneficially owns 10,170,232 shares of Ocular Therapeutix, Inc. common stock.
- This ownership represents 5.8% of the total outstanding common stock of Ocular Therapeutix, Inc.
- BlackRock holds sole voting power over 9,950,244 shares and sole dispositive power over 10,170,232 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Various BlackRock business units and subsidiaries, including BlackRock Advisors, LLC and BlackRock Investment Management (UK) Limited, are involved in the beneficial ownership.
Sentiment
Score: 7
Explanation: BlackRock's continued significant ownership stake in Ocular Therapeutix indicates ongoing institutional confidence, though this filing is a routine ownership disclosure rather than a new investment announcement or a change in company fundamentals.
Positives
- The continued significant ownership by a major institutional investor like BlackRock can signal ongoing confidence in Ocular Therapeutix, Inc.'s long-term prospects.
- BlackRock's certification that the shares are held in the ordinary course of business suggests a passive investment strategy, reducing concerns about potential activist interventions.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Ocular Therapeutix, Inc.'s future performance or BlackRock's future investment intentions beyond the ordinary course of business.
Industry Context
BlackRock's investment in Ocular Therapeutix, a company in the biotechnology sector, reflects a broader trend of institutional investors maintaining positions in healthcare and life sciences companies, often driven by long-term growth potential in medical innovation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-Fact | Previous individuals under the April 30, 2023 Power of Attorney | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 01/21/2025 | Revocation of previous power of attorney and appointment of new attorneys-in-fact for compliance with ownership reporting requirements. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, revoking the prior one dated April 30, 2023, and appointing a new set of individuals to execute documents related to ownership or control-person reporting requirements. | 01/21/2025 | This is an internal corporate governance update for BlackRock, Inc. to ensure proper authorization for SEC and other regulatory filings, with no direct impact on Ocular Therapeutix, Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: The continued significant institutional ownership by BlackRock may be viewed positively, suggesting stability and long-term interest in the company.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of the previously revoked Power of Attorney. |
| 01/21/2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 09/30/2025 | Date of event which requires filing of this statement, representing the reporting period end for beneficial ownership. |
| 10/17/2025 | Signature date of the Schedule 13G/A filing by BlackRock, Inc. |
Recommendation
holdThis Schedule 13G filing is a routine disclosure of BlackRock's beneficial ownership in Ocular Therapeutix, indicating a continued significant institutional stake. While the presence of a major institutional investor like BlackRock is generally a positive indicator of long-term confidence, this specific filing does not present new financial performance data or strategic shifts that would warrant a change in investment recommendation. It primarily confirms an existing ownership position.
Keywords
BlackRock, Ocular Therapeutix, Institutional Ownership, Schedule 13G, Common Stock, Investment, Beneficial Ownership, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.